Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Non-Current Debt (2021 - 2025)

Kezar Life Sciences' Non-Current Debt history spans 5 years, with the latest figure at $1.4 million for Q3 2025.

  • On a quarterly basis, Non-Current Debt fell 78.36% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 78.36% decrease, with the full-year FY2024 number at $5.1 million, down 49.24% from a year prior.
  • Non-Current Debt hit $1.4 million in Q3 2025 for Kezar Life Sciences, down from $2.6 million in the prior quarter.
  • Over the last five years, Non-Current Debt for KZR hit a ceiling of $10.1 million in Q4 2023 and a floor of $1.4 million in Q3 2025.
  • Historically, Non-Current Debt has averaged $7.8 million across 5 years, with a median of $9.6 million in 2021.
  • Biggest five-year swings in Non-Current Debt: rose 2.39% in 2023 and later tumbled 78.36% in 2025.
  • Tracing KZR's Non-Current Debt over 5 years: stood at $9.6 million in 2021, then increased by 2.2% to $9.8 million in 2022, then increased by 2.39% to $10.1 million in 2023, then crashed by 49.24% to $5.1 million in 2024, then tumbled by 73.12% to $1.4 million in 2025.
  • Business Quant data shows Non-Current Debt for KZR at $1.4 million in Q3 2025, $2.6 million in Q2 2025, and $3.9 million in Q1 2025.